BioPharmSignal logoBioPharmSignal

Biotech News

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics (MCRB)Seres TherapeuticsCompany update

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity

Related news

MCRBSeres Therapeutics2026-07-08 11:00 EST

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

MCRBSeres Therapeutics2026-05-05 11:00 EST

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

View all latest news

Seres Therapeutics

Live Biotherapeutic Platform Seres Therapeutics develops live biotherapeutics that alter the gut microbiome to treat inflammatory and immune-mediated disease. The company previously led development of VOWST, the first orally administered FDA-approved microbiome therapeutic, before divesting it to Nestlé Health Science. SER-155 SER-155 is...

Recent company news

MCRBSeres Therapeutics2026-09-08 22:00 EST

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MCRBSeres Therapeutics2026-09-01 11:00 EST

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

MCRBSeres Therapeutics2026-08-05 11:00 EST

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

MCRBSeres Therapeutics2026-07-08 11:00 EST

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

MCRBSeres Therapeutics2026-06-25 11:00 EST

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Stock data

Close
4.10 USD
Market cap
70.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States